sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that Lisa Conte, the company's founder, president, and CEO, will join the Lytham Partners Fall 2024 Investor Conference. The virtual event will occur on October 1, 2024.
The company will host a webcasted presentation at 1:15 PM Eastern on the same day. Viewers can access the webcast through the provided link and it will be available for replay after the event.
Additionally, Jaguar Health's management team will engage in one-on-one meetings with investors throughout the conference. Interested parties can arrange meetings via Lytham Partners by contacting 1x1@lythampartners.com or registering on their website.
Jaguar Health focuses on developing proprietary prescription medicines derived from rainforest plants to address gastrointestinal distress. Their subsidiary, Napo Pharmaceuticals, markets crofelemer under the brand name Mytesi® for noninfectious diarrhea in HIV/AIDS patients. Another subsidiary, Napo Therapeutics in Milan, aims to expand crofelemer's reach in Europe for rare diseases.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.